Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by stockgurukingon Aug 29, 2012 3:54pm

199 Views

Post# 20276086

Financially Derisked!

Going into the Summer the largest risk for ICO shareholders was the financial risk...now with the Summer winding down and the company being funded at
.45 the financing overhang is gone and I don't expect the stock to trade below
.40 for much longer.

Lots of eyeballs on this one on both sides of the border!

Bullboard Posts

Changing Europe’s dependency on HREE from China